



AmesFormer: A Graph Transformer Neural Network for Mutagenicity Prediction

Luke Thompson
Josiah Evans

Supervisor: Slade Matthews



The Ames Test



Mutagenicity Detection is a Contemporary Issue

ACCC recalls more jeans containing hazardous dye linked to cancer

By consumer affairs reporter Amy Bainbridge

Posted Thu 15 May 2014 at 3:53pm, updated Thu 15 May 2014 at 6:34pm



Potential contamination of Australian metformin medicines

Low levels of contamination with N-nitrosodimethylamine (NDMA)

Published: 18 November 2020

[Listen](#) [Print](#) [Share](#)

Textiles recalled after tests for azo dyes

Date 15 May 2014

Topics [Protecting yourself](#)



Five popular sunscreens recalled after a cancer-causing ingredient was added to the batches

Five popular Australian sun safety products have been urgently recalled after a cancer-causing ingredient was detected in the batches.

Georgina Noack

Computational Ames Models




Image: <https://www.fda.gov/drugs/regulatory-science-action/new-developments-regulatory-qsar-modeling-new-qsar-model-predicting-blood-brain-barrier-permeability>

Explosion in AI Research for Pharmacology / Tox

Where are the Ames Models?



Deep Graph Learning with Property Augmentation for Predicting Drug-Induced Liver Injury

Department of Computer Science, University of Texas at Arlington, Arlington, Texas, USA

ACS Omega

Quantitative weight of evidence method for combining predictions of quantitative structure-activity relationship models

Medical Chemistry

Predicting the Biodegradability of Molecular Representations by Using Recurrently with the Graph Attention Mechanism

Jian Gao, Zheyuan Shen, Yufeng Xie, Jialiang Lu, Yang Lu, Sikang Chen, Qingyu Bian, Yue Guo, Liteng Shen, Jian Wu, Binbin Zhou,

Structure-Property Chemical Space Embedding and a Deep Learning Approach for Accurate Prediction of Chemical Properties

Ting Li, Weida Tong, Ruth Roberts, Zhichao Liu, and Shraddha Thakkar

What Do Existing Models Look Like?

- Big Players
 - MN-AM – US FDA-affiliated
 - MIT – World #1 University
- Old Architectures
 - “Classical machine learning”
- Australia uses TIMES_AMES
 - Costs >\$50k / year
- Still not good enough to replace *in vitro* testing

Team or Institution Name	Model Name	BA (%)	F1 Score
MN-AM	ChemTunes. ToxGPS Ames NIHS _{v2}	78.5	0.538
Meiji Pharmaceutical University	MMI-STK2	77.0	0.524
Instem	Leadscope Consensus Model	73.7	0.497
LMC Bourgas University	TIMES_AMES 17.17.3	73.3	0.511
Alttox Ltd.	GeneTox-iS	72.6	0.500
Evergreen AI, Inc.	Avalon	71.9	0.485
MultiCASE Inc.	PHARM_BMUT V1.8.0.0.17691.350	71.2	0.497
Simulations Plus Inc.	S+MUT_NIHS_ABC	71.2	0.421
The University of Sydney	DRSpicySTiM-Ensemble	70.1	0.425
Lhasa Ltd.	Sarah Nexus v.3.0.1 (2068 chemicals)	69.0	0.410
NCTR/FDA	DeepAmes	69.1	0.476
IRFMN	CONSENSUS (18k) V0.9.1	68.1	0.402
Liverpool John Moores University	DL	68.7	0.403
NIBIOHN	GNN(kMoL)_bestbalanced	67.2	0.470
SIOC, CAS	CISOC-PSMT (SIOC, CAS, China)	66.4	0.393
Politecnico di Milano	GCN	65.8	0.444
IdeaConsult Ltd.	AMBIT DeepN v4.85	65.6	0.408
Massachusetts Institute of Technology	Chemprop	64.3	0.420
Chemotargets	CHMT_GBoostSC	64.3	0.414
ISS	Mutagenicity ISS-modified2020	62.8	0.348
Gifu University	xenoBiotic 0.9q	60.3	0.334

How can we Make the Best Ames Model?

- What models performed best on other biology tasks?
 - Benchmark molecular prediction
 - Multi-endpoint toxicity prediction
- Use state-of-the-art techniques from AI literature
 - Transformers – ChatGPT
 - Graph neural networks – Facebook friend recommendation
 - Special encodings – Extra chemical information
 - Harder math 🧐
- A graph transformer?

Hypotheses

We hypothesise a graph transformer for Ames mutagenicity will:

1. Be the most effective when trained on the largest existing Ames datasets
2. Achieve state-of-the-art predictive performance

Table 3: Results on MolHIV.

method	#param.	AUC (%)
GCN-GraphNorm [5, 8]	526K	78.83±1.00
PNA [10]	326K	79.05±1.32
PHC-GNN [29]	111K	79.34±1.16
DeeperGCN-FLAG [30]	532K	79.42±1.20
DGN [2]	114K	79.70±0.97
GIN-VN[54] (fine-tune)	3.3M	77.80±1.82
Graphormer-FLAG	47.0M	80.51±0.53

Image: <http://arxiv.org/pdf/2106.05234.pdf>

The basis of our architecture!

```
{'eval_loss': 1.905617117881775, 'eval_accuracy': {'accuracy': 0.52}, 'eval_precision': {'precision': 0.52}, 'eval_recall': {'recall': 1.0}, 'eval_f1': {'f1': 0.6842105263157895}, 'eval_runtime': 7.133, 'eval_samples_per_second': 7.01, 'eval_steps_per_second': 3.505, 'epoch': 0.8}
{'loss': 0.8136, 'learning_rate': 4.375e-05, 'epoch': 2.0}
12% | ██████████ | 5/40 [00:10<01:03, 1.81s/it]
```

Brateningugh
polargres 🤖

Aims

Hence, we aim to:



- To construct a graph transformer *incorporating our lab's unique domain knowledge*
- To compare the performance of our model with others from the literature
- To deploy this model on our lab website
 - Enabling regulatory, industrial use

[rch](#) [Publications](#) [Tools](#) [Contact](#)

Our research topics

In silico toxicology

Our primary research focus is understanding the adverse effects of chemicals on living organisms. We employ computer-based *in silico* methods to predict the interactions between cellular components and potentially toxic chemicals such as medications, industrial substances, and environmental pollutants. These computations reveal molecular properties which are modelled to a variety of adverse outcomes including cancer, immune sensitisation, and endocrine disruption.



Computer-aided drug design

The knowledge we gain about how chemicals interact with biological systems enables us to adapt our research to design molecules with therapeutic potential. We utilise *in silico* methods to generate drug candidate structures and predict their properties to quantify how well they work. We have successfully applied our techniques on various drug classes including anti-malarials and kinase inhibitors.

Translational and regulatory science

A major element of our work is translating our basic research into practical tools that support real world decisions. We actively collaborate with regulatory scientists to better understand which substances should be prioritised for risk assessment. We also participate in international predictive toxicology and drug design challenges to validate our techniques amongst academic and industry standards.




Our lab website 


Methods

Understanding Neural Networks


Conventional Neural Networks for Mutagenicity



The **Graph** in Graph Transformers



NDMA Structure



Graph Neural Network
Molecular Structure imbued
within the network structure

**Neural
Network**
Processes
aggregated vectors

Ames
Positivity
+/-

Example atom vector

Sp3 Hybridised? \rightarrow 0
Carbon atom? \rightarrow 1
 \vdots
 x_n


Methods

Understanding AmesFormer

The Transformer in Graph Transformers

Attention

- Prioritise the most important atomic features
 - Is chirality more important than conjugation?
- Allow the network to always see its local environment
- Results in much better *learned* molecular representations



The Transformer in Graph Transformers


Centrality encoding

- Introduced at the beginning
- Appended to the atom feature vector
- “How many bonds does this atom make?”

$$\vec{h}_i = \vec{h}_i + z_{\text{deg}(v_i)}$$

Atom feature vector



Bond count



The Transformer in Graph Transformers

Spatial encoding

- Biases the attention – The amount each atom feature attends the others
- “How much does every other atom affect me?”
- Upshot: Pay less attention to distant atoms, as they likely exert less electrostatic forces




The Transformer in Graph Transformers

Edge encoding


- Biases the attention – “How important are the bonds my neighbours form?”
- Basically, the mean of the dot products of all bond features on each shortest path times a bias

Average them! $\frac{1}{N} \sum_{n=1}^N \vec{e}_n \cdot (w_n^E)^T$ Biasing matrix

Dot product bond features along shortest paths




The Architecture of AmesFormer



NDMA Structure

Graph Neural Network
Molecular Structure imbued
within the network structure





Results

Hypothesis 1 – Is more data always better?

Testing Our Hypotheses – Is More Data Better?

- We trained three models – One on each Ames dataset
 - Surprisingly, the 2nd largest dataset produced the best performing model




Testing Our Hypotheses – Is More Data Better?

- We trained three models – One on each Ames dataset
 - Surprisingly, the 2nd largest dataset produced the best performing model


Model	AmesFormer-Hansen	AmesFormer-Honma	AmesFormer-Combined
Mean BA (%)	60.6 \pm 0.1	69.2 \pm 0.1	67.8 \pm 0.2
Mean F1	0.320 \pm 0.1	0.426 \pm 0.1	0.414 \pm 0.2
ECE	0.196 \pm 0.159	0.197 \pm 0.123	0.157 \pm 0.154
Best epoch	80	55	50
Best validation loss	0.492	0.916	0.667

Understanding Our Results – Why isn't More Data Better?

- The best dataset showed the most chemical diversity – Silhouette Score of 0.488
 - Others had silhouettes of 0.378 and 0.384
 - I.e. It covered the broadest range of molecular structures



(c) Honma dataset PCA.



(d) UMAP clusters of the Honma dataset.

Results

Hypothesis 2 – Is Our Model State-of-the-Art?

Testing Our Hypotheses – Is Our Model State-of-the-Art?

- Our model is the third best predictor of Ames mutagenicity
- We beat several established teams & companies
- Significant improvement (3.9%) over previous lab result

Team or Institution Name	Model Name	BA (%)	F1 Score
MN-AM	ChemTunes. ToxGPS Ames NIHS _v 2	78.5	0.538
Meiji Pharmaceutical University	MMI-STK2	77.0	0.524
Our result	AmesFormer-Pro	74.0	0.479
Instem	Leadscope Consensus Model	73.7	0.497
LMC Bourgas University	TIMES_AMES 17.17.3	73.3	0.511
Alttox Ltd.	GeneTox-iS	72.6	0.500
Evergreen AI, Inc.	Avalon	71.9	0.485
MultiCASE Inc.	PHARM_BMUT V1.8.0.0.17691.350	71.2	0.497
Simulations Plus Inc.	S+MUT_NIHS_ABC	71.2	0.421
The University of Sydney	DRSpicySTiM-Ensemble	70.1	0.425
Lhasa Ltd.	Sarah Nexus v.3.0.1 (2068 chemicals)	69.0	0.410
NCTR/FDA	DeepAmes	69.1	0.476
IRFMN	CONSENSUS (18k) V0.9.1	68.1	0.402
Liverpool John Moores University	DL	68.7	0.403
NIBIOHN	GNN(kMoL)_bestbalanced	67.2	0.470
SIOC, CAS	CISOC-PSMT (SIOC, CAS, China)	66.4	0.393
Politecnico di Milano	GCN	65.8	0.444
IdeaConsult Ltd.	AMBIT DeepN v4.85	65.6	0.408
Massachusetts Institute of Technology	Chemprop	64.3	0.420
Chemotargets	CHMT_GBoostSC	64.3	0.414
ISS	Mutagenicity ISS-modified2020	62.8	0.348
Gifu University	xenoBiotic 0.9q	60.3	0.334

Understanding Our Results – Why is AmesFormer so Good?

- Representational Power
 - **We can always tell different molecules apart**
 - Earlier models use those “bit vectors”, these are **condensed** representations of the molecule
 - Hence, similar, but pharmacologically distinct molecules can produce the same vector, and thus same prediction, despite differing toxicity
 - This is known as *bit clashing*

Why doesn't AmesFormer suffer the same problem?

Understanding Our Results – Why is AmesFormer so Good?

1. Representational Power via the W-L Test

- **We avoid this problem using our spatial encoding**
- The spatial encoding is equivalent to the shortest-path-enhanced Weisfeiler-Lehman graph isomorphism test
- An inductive proof is available in Chengxuan, et al. 2021

A.1 SPD can Be Used to Improve WL-Test




Figure 2: These two graphs cannot be distinguished by 1-WL-test. But the SPD sets, i.e., the SPD from each node to others, are different: The two types of nodes in the left graph have SPD sets $\{0, 1, 1, 2, 2, 3\}$, $\{0, 1, 1, 1, 2, 2\}$ while the nodes in the right graph have SPD sets $\{0, 1, 1, 2, 3, 3\}$, $\{0, 1, 1, 1, 2, 2\}$.

Understanding Our Results – Why is AmesFormer so Good?

2. Representational Power via the Graph Laplacian
 - **Our GNN can differentiate any two graphs which differ in the spectral properties of their graph Laplacian**
 - A constructive proof is shown in Kanatsoulis & Ribeiro, 2023

Laplacian \mathbf{L} of a graph G is defined as:

$$\mathbf{L} = \mathbf{D} - \mathbf{A}, \tag{4.3}$$

where \mathbf{D} is the degree matrix and \mathbf{A} is the adjacency matrix. Two graphs G and G' are distinguished if their Laplacians have different eigenvalues:

$$\lambda_i(G) \neq \lambda_i(G') \text{ for some eigenvalue } \lambda_i. \tag{4.4}$$

Understanding Our Results – Why is AmesFormer so Good?

3. The Power of the Transformer

- **Transformers have come to dominate complex ML tasks**
 - Text – 2017, Vaswani
 - Vision – 2019, Ramachandran
- Previous good results in non-mutagenicity QSARs.
- **Perhaps unsurprising they also perform well for Ames**

TITLE	CITED BY	YEAR
Attention is all you need A Vaswani Advances in Neural Information Processing Systems	136231	2017


They're this good!

Certainty

How do we Know These Results are
Accurate?


Bayesian Uncertainty Estimation via MC Dropout

- We use Monte Carlo (MC) dropout to generate CIs for our results – BAC



Bayesian Uncertainty Estimation via MC Dropout

- We use Monte Carlo (MC) dropout to generate CIs for our results – F1




(b) The median calibration curve of AmesFormer-Honma over 1000 Monte Carlo dropout samples with an associated **ECE** of 0.197 (95% CI: 0.087, 0.333).


Bayesian Uncertainty Estimation via MC Dropout

- But...
 - We can extend this methodology to the regulatory context by sampling the uncertainty of our inference (i.e., when we are using the model live)
 - Over 1 000 passes we are integrating under the distribution of predictions to gauge our uncertainty
 - **We can therefore sample our uncertainty for the prediction of that *particular* chemical**
 - Recommended by the OECD QSAR Reporting Guideline


Bayesian Uncertainty Estimation via MC Dropout



Bayesian Uncertainty Estimation via MC Dropout




Bayesian Uncertainty Estimation via MC Dropout




Feed Forward Network
The FFN in the Transformer
Diagram

Bayesian Uncertainty Estimation via MC Dropout



Bayesian Uncertainty Estimation via MC Dropout



Future Directions

One Hard Thing That Sounds Easy

Future Directions – Taking the #1 Spot

- Our performance is very good, but two models are better – Why?
- Both better models are “ensembles”
 - Combinations of multiple different models – Logistic regression, simpler graphs, etc
- These models **can see** *whole graph* properties – Solubility, etc
- AmesFormer **cannot see** these properties, it only sees the more detailed atom and bond information

How can we incorporate these *whole molecule* properties into AmesFormer?

Future Directions – Taking the #1 Spot

It's tough...

Node-wise Approach

- Add whole-graph data to each atom
- Pros
 - Done in literature (GraphGPS)
 - Trivial to implement
- Cons
 - Massive data duplication – There's only one set of graph properties, but we add them to every node
 - Computationally inefficient

Attentional Approach

- Add whole-graph data to the graph attention calculation
- Pros
 - No duplication – Improved efficiency
- Cons
 - Unproven
 - Hard to implement
 - Network can't "see" whole-graph data before attention, less opportunities to incorporate it into the molecular representation

Future Directions

One Easy(ish) Thing That Sounds Hard

Future Directions – Improving Accessibility

- Our models are relatively efficient, but still required days to train on a \$US 2000 graphics card
 - More complex tasks would take considerably be longer
 - Multiple endpoint toxicity or ADME
- This is **out of reach** for many small academic labs & startups

How can we make our model more computationally efficient and accessible to compute-poor users?

Future Directions – Improving Accessibility

- Improve **attention**
 - The most computationally expensive part of AmesFormer
- Currently, we do multiple attention calculations in parallel
 - Each attention *head* learns different things to “attend” – Great performance!
 - But do all heads actually learn to attend something valuable?
 - **No** – So, can we:
 - Remove useless heads, retain the good ones?
 - Maintain the same performance whilst improving computational efficiency?

We can use GFiSH-Former by Tan, et al. 2022 to accomplish this


Future Directions – Improving Accessibility

1. Eigenvalue decomposition – Attention covariance matrices are low-rank 🧐
 - I.e., Most of the information in them is useless, we only need the most important 10%
2. Calculate ~3 heads – This should be enough to capture ~90% of variance
 - Way less than the 32 currently calculated for AmesFormer
3. Calculate the remaining 29 as a *finite admixture* of those 3

Future Directions – Improving Accessibility


The head we're calculating

E.g., head 4


$$\mathbf{A}_j = \sum_{k=1}^M \phi(p_{kj}(\mathbf{Q}_k \mathbf{K}_k^\top + \sigma_k \odot \epsilon_j)), \quad \epsilon \sim \mathcal{N}(0, \mathbf{I}),$$

Future Directions – Improving Accessibility


Is a mixture of our 3
main heads M


$$\mathbf{A}_j = \sum_{k=1}^M \phi(p_{kj}(\mathbf{Q}_k \mathbf{K}_k^\top + \sigma_k \odot \epsilon_j)), \quad \epsilon \sim \mathcal{N}(0, \mathbf{I}),$$

Future Directions – Improving Accessibility


With a non-linear transformation

E.g., Gaussian


$$\mathbf{A}_j = \sum_{k=1}^M \phi(p_{kj}(\mathbf{Q}_k \mathbf{K}_k^\top + \sigma_k \odot \epsilon_j)), \quad \epsilon \sim \mathcal{N}(0, \mathbf{I}),$$


Future Directions – Improving Accessibility

Weighted by a parameter determining much each of the 3 main heads should contribute


$$\mathbf{A}_j = \sum_{k=1}^M \phi(p_{kj}(\mathbf{Q}_k \mathbf{K}_k^\top + \sigma_k \odot \epsilon_j)), \quad \epsilon \sim \mathcal{N}(0, \mathbf{I}),$$


Future Directions – Improving Accessibility

Where this is the actual content of the
main head (e.g., head 2)


$$\mathbf{A}_j = \sum_{k=1}^M \phi(p_{kj} (\mathbf{Q}_k \mathbf{K}_k^\top + \sigma_k \odot \epsilon_j)), \quad \epsilon \sim \mathcal{N}(0, \mathbf{I}),$$

Future Directions – Improving Accessibility


Perturbed by some isotropic Gaussian noise sampled from a distribution with mean 0 and covariance of the identity matrix

$$\mathbf{A}_j = \sum_{k=1}^M \phi(p_{kj}(\mathbf{Q}_k \mathbf{K}_k^\top + \sigma_k \odot \epsilon_j)), \quad \epsilon \sim \mathcal{N}(0, \mathbf{I}),$$


Future Directions

With these improvements we can:

- Improve performance
- Democratisise access to QSAR
- Improve regulatory outcomes



Summary

- Ames is important for public safety
- We take advantage of the recent explosion in AI research & apply it to Ames
- Our graph transformer is state-of-the-art
- Serious potential for regulatory application